In addition, HDACi have been shown to target blood cancer-specific pathways, such as BCL6 overexpression in B-cell lymphoma [260], aggresome dependency in multiple myeloma [261,262], and HDAC6 overexpression in lymphoma [250]. Here, HDAC6 is linked to lymphoma.